UT-Southwestern Medical Center: Drug Targeting Clear Cell Renal Cell Carcinoma Shows Promising Approach
April 24, 2024
April 24, 2024
DALLAS, Texas, April 24 (TNSres) -- The University of Texas Southwestern Medical Center issued the following news release:
In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center, a short interfering RNA (siRNA) drug directed to tumor cells effectively disrupted HIF2a, a key driver of clear cell renal cell carcinoma (ccRCC). Published in Clinical Cancer Research, the findings illustrate the potential of siRNA for cancer therapy.
Developed by A . . .
In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center, a short interfering RNA (siRNA) drug directed to tumor cells effectively disrupted HIF2a, a key driver of clear cell renal cell carcinoma (ccRCC). Published in Clinical Cancer Research, the findings illustrate the potential of siRNA for cancer therapy.
Developed by A . . .